Goldman Sachs analyst Salveen Richter downgraded Vertex Pharmaceuticals to Buy from Conviction Buy as part of the firm’s “US Conviction List – Directors’ Cut” for March. Goldman removed Apple (AAPL), Merck (MRK), and Vertex Pharmaceuticals (VRTX) from its Conviction List.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals CSO Altshuler sells 3,002 common shares
- Vertex Pharmaceuticals reports CHMP opinion for label extension of Kalydeco
- Crispr Therapeutics price target raised to $112 from $110 at Chardan
- A New Cause for Concern: Vertex Pharmaceuticals Inc. Adds a New Regulation Risk
- Vertex Pharmaceuticals initiated with an Outperform at Wolfe Research
